Michał Dębczyński

Dr. Michał Dębczyński


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Archive of International Journal of Cancer and Allied Science
Verified
Journal Article
Open access
PDF file
DMDamian Mojsak
Damian Mojsak
MDMichał Dębczyński
Michał Dębczyński
BKBeata Kuklińska
Beata Kuklińska
RMRobert M. Mróz
Robert M. Mróz
Ewing's sarcoma, a rare and highly aggressive tumor, is prone to recurrence even after extensive surgery and often metastasizes early. Typically seen in children and adolescents aged 10-20 years, it affects older individuals in approximately 30% of cases. This report details a 58-year-old man presenting with a foot tumor, back pain, and left leg discomfort. A chest x-ray revealing a lung mass led to a referral to the Pulmonology Department, but the diagnosis was delayed for months, worsening the prognosis of this aggressive malignancy. The COVID-19 pandemic has significantly disrupted global healthcare, redirecting resources and delaying the diagnosis of non-COVID conditions. This has resulted in more patients presenting with advanced disease, limiting treatment options. Patient fear of infection further complicates timely diagnosis. This case underscores the impact of the pandemic on oncology care.

27 September 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
MDMichał Dębczyński
Michał Dębczyński
GGGiulia Gorrieri
Giulia Gorrieri
DMDamian Mojsak
Damian Mojsak
FGFloriana Guida
Floriana Guida
FZFederico Zara
Federico Zara
Paolo ScudieriPaolo Scudieri
Paolo Scudieri
ATP12A encodes the catalytic subunit of the non-gastric proton pump, which is expressed in many epithelial tissues and mediates the secretion of protons in exchange for potassium ions. In the airways, ATP12A-dependent proton secretion contributes to complex mechanisms regulating the composition and properties of the fluid and mucus lining the respiratory epithelia, which are essential to maintain the airway host defense and the respiratory health. Increased expression and activity of ATP12A in combination with the loss of other balancing activities, such as the bicarbonate secretion mediated by CFTR, leads to excessive acidification of the airway surface liquid and mucus dysfunction, processes that play relevant roles in the pathogenesis of cystic fibrosis and other chronic inflammatory respiratory disorders. In this review, we summarize the findings dealing with ATP12A expression, function, and modulation in the airways, which led to the consideration of ATP12A as a potential therapeutic target for the treatment of cystic fibrosis and other airway diseases; we also highlight the current advances and gaps regarding the development of therapeutic strategies aimed at ATP12A inhibition.

27 April 2022 in American Journal of Case Reports
Verified
Journal Article
Open access
DMDamian Mojsak
Damian Mojsak
MDMichał Dębczyński
Michał Dębczyński
BKBeata Kuklińska
Beata Kuklińska
AMAnna Moniuszko-Malinowska
Anna Moniuszko-Malinowska
RMRobert Marek Mróz
Robert Marek Mróz
Rare disease Advanced non-small cell lung cancer has poor prognosis and low survival. Immunotherapy with the use of immune checkpoint inhibitors is a relatively new method of treatment that offers a chance to significantly extend the survival and quality of life of patients over that obtained with conventional chemotherapy. One of the complications of immunotherapy is immune checkpoint inhibitor-related pneumonitis. We analyzed the available medical data on the treatment of 22 patients with non-small cell lung cancer who were treated in our clinic and qualified for immunotherapy with one of the anti-PD-1/anti-PD-L1 agents: nivolumab, atezolizumab, or pembrolizumab. In this group of patients treated with immune checkpoint inhibitors, 4 patients experienced immune checkpoint inhibitor-related pneumonitis. Immune checkpoint inhibitor-related pneumonitis is a rare but potentially life-threatening complication of immune therapy. It can manifest in many ways, from asymptomatic to severe cases, which require quick action and treatment. Knowing the spectrum of symptoms and being alert to the possibility of such a complication is an important skill for doctors who use immunotherapy in their patients.

Verified
Journal Article
Open access
PDF file
MDMichał Dębczyński
Michał Dębczyński
KGKatarzyna Guziejko
Katarzyna Guziejko
RMRobert Marek Mróz
Robert Marek Mróz
Chronic obstructive pulmonary disease (COPD) is a common, chronic and progressive disease that is a major public health problem worldwide. Treatment for stable COPD relies on pharmacological and non-pharmacological procedures. Education, self-management interventions and personalized pulmonary rehabilitation should be part of chronic care for patients with COPD at all stages of their disease. The comprehensive care should be provided by integrated pulmonary care based on pulmonary centers and a multidisciplinary team to all patients with COPD. Holistic approach to the patient with COPD and his involvement in therapy and working closely with healthcare professionals will improve quality of life of COPD patients. It also modifies the course of the disease, prevents progression and may reduce the frequency of exacerbations. In this article, we present the proposed model of integrated pulmonary care, structures necessary for multidisciplinary treatment and self-management intervention as essential elements in the treatment of patients with COPD. Chronic obstructive pulmonary disease (COPD) is a common, chronic and progressive disease that is a major public health problem worldwide. Treatment for stable COPD relies on pharmacological and non-pharmacological procedures. Education, self-management interventions and personalized pulmonary rehabilitation should be part of chronic care for patients with COPD at all stages of their disease. The comprehensive care should be provided by integrated pulmonary care based on pulmonary centers and a multidisciplinary team to all patients with COPD. Holistic approach to the patient with COPD and his involvement in therapy and working closely with healthcare professionals will improve quality of life of COPD patients. It also modifies the course of the disease, prevents progression and may reduce the frequency of exacerbations. In this article, we present the proposed model of integrated pulmonary care, structures necessary for multidisciplinary treatment and self-management intervention as essential elements in the treatment of patients with COPD.

11 August 2022 in American Journal of Case Reports
Verified
Journal Article
Open access
MDMichał Dębczyński
Michał Dębczyński
DMDamian Mojsak
Damian Mojsak
BKBeata Kuklińska
Beata Kuklińska
RMRobert Marek Mróz
Robert Marek Mróz
Unusual clinical course : Atezolizumab is an immune checkpoint inhibitor used as first-line treatment with carboplatin and etoposide chemotherapy for advanced small cell lung cancer. Immunochemotherapy treatment decisions can be affected by patients’ physical ability. Because of the exclusion of patients with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥2 from clinical trials, treatment outcome evidence in this group is limited. We present the case of a 75-year-old woman with an ECOG PS of 2 admitted with respiratory symptoms and diagnosed with advanced small-cell lung cancer. After managing exacerbation of COPD and decompensated heart failure, atezolizumab with carboplatin and etoposide was administered. After 2 cycles of immunochemo-therapy, deterioration of health was observed, including anemia and thrombocytopenia. Because of the good response in imaging tests and restored balance of the patient condition, immunochemotherapy was continued. After 4 cycles of combined treatment, complete regression was achieved. No another adverse effects were observed. The patient was qualified for maintenance therapy with atezolizumab. In follow-up CT scan after 2 cycles of atezolizumab, progression was observed and patient was qualified for second-line treatment. This report presents the case of an older patient with advanced small cell lung cancer and an ECOG status of 2 who responded to combined immunochemotherapy with atezolizumab, etoposide, and carboplatin. Adverse effects observed during immunotherapy were not a reason for discontinuation of the therapy. The assessment of the effectiveness of immunotherapy in patients with ECOG PS ≥2 is difficult owing to the insufficient representation of this group in clinical trials.